Table 7.

Additional study in psoriasis

Clinical study number/name	Study phase	Study details	Status
NCT00329303	Phase 2 extension	Extension of NCT00245765 to assess the re-treatment of those patients who responded to treatment in the first trial but relapsed during the no-treatment period. No placebo patients from NCT00245765 entered this study due to their lack of response in the first study.	Completed
		Patients continued with their dosing schedule from NCT00245765.
		N = 75 active CD patients from NCT00245765.
		Primary endpoint: No difference between the PASI scores at the end of the initial and the re-treatment periods (achieved).

CZP was administered subcutaneously. CD, Crohn disease; PASI, Psoriasis Area and Severity Index.